Easterly Investment Partners LLC Has $1.12 Million Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Easterly Investment Partners LLC cut its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 80.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 61,454 shares of the life sciences company’s stock after selling 245,700 shares during the quarter. Easterly Investment Partners LLC’s holdings in Integra LifeSciences were worth $1,117,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. CWM LLC lifted its stake in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 425 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after buying an additional 444 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Integra LifeSciences by 1.1% in the first quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock valued at $1,764,000 after buying an additional 551 shares in the last quarter. Texas Permanent School Fund Corp grew its position in Integra LifeSciences by 1.5% in the first quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company’s stock valued at $2,110,000 after acquiring an additional 870 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Integra LifeSciences by 7.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company’s stock worth $421,000 after acquiring an additional 1,010 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Down 2.9 %

Shares of NASDAQ IART opened at $24.78 on Friday. The company’s 50 day moving average price is $19.08 and its 200-day moving average price is $24.38. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.10 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42. The company has a market capitalization of $1.91 billion, a P/E ratio of -275.30, a price-to-earnings-growth ratio of 0.91 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the business posted $0.76 EPS. The business’s revenue was down .4% compared to the same quarter last year. Equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IART. Citigroup lifted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday. Morgan Stanley upped their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. JMP Securities dropped their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Finally, Bank of America reduced their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $27.25.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.